A review of one research paper.

Our review questions

Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP‑1 receptor agonist, compared with placebo and open‑label semaglutide in people with type 2 diabetes: a randomised clinical trial

Study review

In preparation

Not independently approved.

Paper published: Not recorded

Study at a glance

DOI
10.1007/s00125-023-06053-9

Key limitation: A full assessment of this paper is not yet available. Its presence in the library does not establish benefit or safety.

0

Review in preparation

This paper has a dedicated review record, but its full study appraisal is not yet available. It has not been counted as a completed review.

0 of 15 questions answered; 0 partly resolved; 15 awaiting assessment.

The original paper and references remain available above.